American Skin Association Announces Research Achievement Awards
AMY S. PALLER, MD 2021 RECIPIENT OF DAVID MARTIN CARTER MENTOR AWARD
News provided by
Share this article
Share this article
2021 David Martin Carter Mentor Award and the
2021 Research Achievement Awards.
For over three decades, ASA s
David Martin Carter Mentor Award has honored members of the dermatology community who embody the characteristics that made the late Dr. David Martin Carter an inspiration to dermatologists, investigators, and medical students throughout the world. Dr. Carter and ASA s late founder, Dr. George Hambrick, worked tirelessly to grow the organization into a leading force to defeat melanoma, skin cancer and other skin diseases.
Sugary beverage linked to increased risk of colorectal cancer in women under 50: Study ANI | Updated: May 07, 2021 08:11 IST
Washington [US], May 7 (ANI): If you are obsessed with sugar-sweetened drinks then you need to think twice before having them regularly.
A new study led by Washington University School of Medicine has found a link between drinking sugar-sweetened beverages and an increased risk of developing colorectal cancer in women under age 50. The findings suggest that heavy consumption of sugary drinks during adolescence (ages 13 to 18) and adulthood can increase the disease risk.
The study, published in the journal Gut, provides more support for public health efforts that encourage people to reduce the amount of sugar they consume.
Early-Onset Colorectal Cancer — Are Sugary Drinks to Blame? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Date Time
Finding alternatives to traditional antibiotics aim of $11 million grant
Researchers at Washington University School of Medicine in St. Louis have received an $11 million grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) to find new ways to combat the growing threat of antibiotic resistance.
The grant funds a two-pronged approach. One aims to identify and develop alternatives to antibiotics for urinary tract infections (UTIs) and other infections caused by drug-resistant bacteria. The other is exploring the potential for antibiotic development of GmPcides, a novel class of molecules that kills a wide variety of bacteria in the lab when used alone, and boosts the bacteria-killing properties of other antibiotics when used in combination with them.